Deborah Hunter
Incyte (United States) · 44 works · 6,112 citations · h-index 26
Top works
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- CCR2 modulates inflammatory and metabolic effects of high-fat feeding
- Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- Activation of a Novel Calcium-dependent Protein-tyrosine Kinase
- Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- A Calcium-dependent Tyrosine Kinase Splice Variant in Human Monocytes
- Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)
- Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
- An Intracellular Calcium Signal Activates p70 but Not p90 Ribosomal S6 Kinase in Liver Epithelial Cells
- Uterine leiomyoma in the Eker rat: A unique model for important diseases of women
- Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
- The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)
- Uterine Leiomyomas: Mechanisms of Tumorigenesis
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- Phosphatidylinositol 3-kinase but not tuberin is required for PDGF-induced cell migration
- Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).
- A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies